ClinicalTrials.gg
CompletedNCT06910358APOLLOUpdated Oct 9, 2026

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

A Phase 3 interventional study of Placebo and DISC-1459 in Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP), sponsored by Disc Medicine, Inc. Completed at 27 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Disc Medicine, Inc · Phase 3, Interventional, and Treatment

Updated Oct 9, 2026Now CompletedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Protoporphyria, Erythropoietic with a site in United States — 4 open to participants now, 4 under way, 2 of them phase 3. Protoporphyria, Erythropoietic · United States.

Enrollment
3rd of 13
183 · median 77
Started
2025
with 1 other
Phase 3
3 of 18
none open now
Registered
14th of 18
by date
Lead sponsor
4 of 18
Disc Medicine, Inc

Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 3, and was the 14th registered.

Protoporphyria, Erythropoietic

29 studies on the registry are indexed under Protoporphyria, Erythropoietic; 5 are open to participants now.

Browse Protoporphyria, Erythropoietic studies →

Open to participants now

4 of the 18 studies in Protoporphyria, Erythropoietic with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Protoporphyria, Erythropoietic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Protoporphyria, Erythropoietic with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are:

  • Whether bitopertin increases pain-free sunlight exposure after 6 months of treatment in participants with EPP or XLP.
  • How PPIX concentration levels change from before bitopertin treatment to after 6 months of treatment.

Researchers will compare bitopertin to a placebo look-alike substance that contains no drug.

Participants will complete daily questionnaires and attend study visits for assessments.

03

Conditions studied

  • Erythropoietic Protoporphyria (EPP)
  • X-Linked Protoporphyria (XLP)

Keywords

  • EPP
  • XLP
  • DISC-1459
  • RO4917838
  • porphyria
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 12 years or older at the time of study consent.
  2. Diagnosis of EPP or XLP, based on medical history by ferrochelatase (FECH) or aminolevulinic acid synthase 2 (ALAS2) genotyping or by biochemical porphyrin analysis.
  3. Minimum daily Sun Exposure Diary compliance ≥85% on Days -14 through Day -1, inclusive, during screening, and at least 1 successfully completed Sun Exposure Challenge (adults only, as this assessment is optional for adolescents) or historical recall of time to prodrome
  4. Body weight ≥32 kg (ages 12 to \<18 years), ≥18.5 kg/m2 (ages ≥18 years) at screening.
  5. of at least 2 months prior to screening of afamelanotide and dersimelagon, if applicable.
  6. and alanine transaminase \<3× (ULN)and total \<2× ULN (unless documented Gilbert syndrome) at screening. Albumin >lower limit of normal (LLN).
  7. Willing to practice highly effective methods of (both males who have partners of and females of childbearing potential during screening, while taking study drug, and for at least 30 days after the last dose of study drug).

Exclusion criteria

Exclusion Criteria:

  1. Major surgery within 8 weeks before screening or incomplete recovery from any previous surgery.
  2. Other than EPP or XLP, an inherited intrinsic or extrinsic red cell disease associated with anemia.
  3. Known to any component of the study drug.
  4. History of liver transplantation or anticipated need for liver transplantation.
  5. History of alcohol dependence or excessive alcohol consumption, as assessed by the Investigator.
  6. Active (HIV), active or C.
  7. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study.
  8. Condition or concomitant medication that would confound the ability to interpret clinical, clinical laboratory, or participant diary data, including a major psychiatric condition that has had an exacerbation or required hospitalization in the last 6 months.

    Treatment History:

  9. Prior exposure to bitopertin.
  10. Concurrent or planned treatment with afamelanotide or dersimelagon during the study period.
  11. Treatment with opioids for any period >7 days in the 2 months prior to screening or anticipated to require opioid use for >7 days at any point during the study.
  12. New treatment for anemia, including initiation of iron supplementation, within 1 month of screening.
  13. Current or planned use of any drugs or herbal remedies known to be strong or moderate inhibitors or inducers of cytochrome P450 (CYP)3A4 enzymes for 28 days prior to the first dose and throughout the study.
  14. Current or planned treatment with antipsychotic medication.

    Laboratory Exclusions:

  15. \<10 g/dL at screening.

    Miscellaneous:

  16. Participation in other interventional clinical studies within 30 days prior to screening.
  17. If female, pregnant or breastfeeding.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
183 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    DISC-1459 oral dose

    Drug: DISC-1459

Interventions

  • DrugPlacebo

    Oral dose, once a day for 24 weeks

  • Oral dose, once a day for 24 weeks

    Also known as: Bitopertin, RO4917838

06

What researchers measure

Primary outcomes

  1. Average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 to 18:00 (10:00 AM to 6:00 PM) after 6 months (24 weeks) of treatment

    Time frame: 24 weeks

  2. Percent change from baseline in whole-blood metal-free PPIX levels at 6 months

    Time frame: 24 weeks

  3. Safety and tolerability, as assessed by adverse events (AEs) and laboratory results, over the 6-month treatment period

    Time frame: 24 weeks

Secondary outcomes

  1. Occurrence of phototoxic reactions over the 6-month treatment period

    Time frame: 24 weeks

  2. Cumulative total time in sunlight on days without pain from a phototoxic reaction between 10:00 to 18:00 (10:00 AM to 6:00 PM) over the 6-month (24-week) treatment period

    Time frame: 24 weeks

  3. Change from baseline in 2-week average daily sunlight exposure time (minutes) to first prodromal symptom (eg, burning, tingling, itching, or stinging) associated with sunlight exposure between 1 hour post-sunrise and 1 hour pre-sunset at 6 months

    Time frame: 24 weeks

07

Study locations

27 sites
  • Marvel Clinical Research
    Huntington Beach, California 92647, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33146, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02115, United States
  • MetroBoston Clinical Partners
    Boston, Massachusetts 02135, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Wake Forest University
    Winston-Salem, North Carolina 27157, United States
  • Remington-Davis Clinical Research
    Columbus, Ohio 43215, United States
  • University of Texas Medical Branch
    Galveston, Texas 77550, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • UZ Leuven
    Leuven, 3000, Belgium
  • University of Alberta
    Edmonton, Alberta T6G 2R3, Canada
  • CHU de Nantes - Hôtel Dieu, Service de dermatologie
    Nantes, France 44093, France
  • Centre d'Investigation Clinique (CIC) Hôpital Bichat - Claude-Bernard
    Paris, France 75018, France
  • Charité - Universitätsmedizin Berlin, Institute of Allergology
    Berlin, Germany 12203, Germany
  • Klinikum Chemnitz gGmbH
    Chemnitz, Saxony 09116, Germany
  • Children's Health Ireland (CHI)
    Dublin, D12N512, Ireland
  • Instituto Dermatologico San Gallicano Istituti Fisioterapici Ospitalieri IRCCS
    Roma, 53-00144, Italy
  • Erasmus MC
    Rotterdam, The Netherlands 3015 GD, Netherlands
  • Hospital Clinic de Barcelona
    Barcelona, Spain 08036, Spain
  • Karolinska University Hospital
    Stockholm, Sweden 141 86, Sweden
  • Guy's and St Thomas' NHS Foundation Trust
    London, England SE1 9RT, United Kingdom
  • Clinical Research Centre, Ninewells Hospital & Medical School , NHS Tayside
    Dundee, Scotland DD1 9SY, United Kingdom
  • Photobiology Unit, Salford Royal Hospital
    Salford, M6 8HD, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2025 to primary completion in Sep 2026, 17 months.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Apr 4, 2025
StartActual
Apr 4, 2025
Primary completionActual
Sep 8, 2026
CompletionActual
Sep 8, 2026was Oct 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 9, 2026
Study completion
Oct 2026→Sep 8, 2026 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Active, not recruiting→Completed
    Study completion Oct 2026→Sep 8, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06910358
Lead sponsor
Disc Medicine, Inc
Responsible party
Sponsor
First posted
Apr 4, 2025
Start date
Apr 4, 2025
Primary completion
Sep 8, 2026
Completion
Sep 8, 2026
Last update
Oct 9, 2026

Study contacts

Will Savage, MD, PhD
study director · Disc Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bitopertin

Start the discussion